Compare GERN & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GERN | SLRC |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.3M | 771.9M |
| IPO Year | 1996 | 2010 |
| Metric | GERN | SLRC |
|---|---|---|
| Price | $1.37 | $15.64 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 7 |
| Target Price | $3.00 | ★ $16.04 |
| AVG Volume (30 Days) | ★ 6.9M | 264.5K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 10.47% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.65 |
| Revenue | $183,403,000.00 | ★ $219,666,000.00 |
| Revenue This Year | $147.34 | N/A |
| Revenue Next Year | $39.11 | N/A |
| P/E Ratio | ★ N/A | $9.48 |
| Revenue Growth | ★ 522.13 | N/A |
| 52 Week Low | $1.04 | $13.64 |
| 52 Week High | $4.01 | $17.94 |
| Indicator | GERN | SLRC |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 49.50 |
| Support Level | $1.21 | $15.97 |
| Resistance Level | $1.42 | $16.14 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 85.48 | 36.52 |
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.